Degeneration of Spared Axons Following Partial White Matter Lesion: Implications for Optic Nerve Neuropathies

Neuroprotective therapy is a relatively new development in the approach to the treatment of acute and chronic brain damage. Though initially viewed in the framework of acute CNS injuries, the concept was recently extended to include chronic injuries, in which at any given time there are some neurons in an acute phase of degeneration coexisting with others that are healthy, marginally damaged, or dead. The healthy neurons and those that are only marginally damaged are the potential targets for neuroprotection. For the development of neuroprotective therapies, it is essential to employ an animal model in which the damage resulting from secondary degeneration can be quantitatively distinguished from primary degeneration. This is of particular relevance when the site of the damage is in the white matter (nerve fibers) rather than in the gray matter (cell bodies). In the present work we reexamine the concepts of secondary degeneration and neuroprotection in white matter lesions. Using a partial crush injury of the adult rat optic nerve as a model, we were able to assess both primary and secondary nerve damage. We show that neurons whose axons were not damaged or only marginally damaged after an acute insult will eventually degenerate as a consequence of their existence in the degenerative environment produced by the injury. This secondary degeneration does not occur in all of the neurons at once, but affects them in a stepwise fashion related to the severity of the damage inflicted. These findings, which may be applicable to the progression of acute or chronic neuropathy, imply that neuroprotective therapy may have a beneficial effect even if there is a time lag between injury and treatment.

[1]  E. Yoles,et al.  HU-211, a nonpsychotropic cannabinoid, produces short- and long-term neuroprotection after optic nerve axotomy. , 1996, Journal of neurotrauma.

[2]  M. Schwab,et al.  Secondary Cell Death and the Inflammatory Reaction After Dorsal Hemisection of the Rat Spinal Cord , 1994, The European journal of neuroscience.

[3]  S M Podos,et al.  The nerve of glaucoma! , 1994, Archives of ophthalmology.

[4]  J. Morgan Selective cell death in glaucoma: does it really occur? , 1994, The British journal of ophthalmology.

[5]  M. Mattson,et al.  Endogenous neuroprotection factors and traumatic brain injury: mechanisms of action and implications for therapy. , 1994, Journal of neurotrauma.

[6]  C. Olanow A radical hypothesis for neurodegeneration , 1993, Trends in Neurosciences.

[7]  R E Lenkinski,et al.  Magnetization transfer imaging of diffuse axonal injury following experimental brain injury in the pig: characterization by magnetization transfer ratio with histopathologic correlation. , 1996, Journal of computer assisted tomography.

[8]  T. Thompson,et al.  Atrophy and Degeneration of Ganglion Cells in Central Retina Following Loss of Postsynaptic Target Neurons in the Dorsal Lateral Geniculate Nucleus of the Adult Cat , 1993, Experimental Neurology.

[9]  A. Faden Pharmacologic treatment of acute traumatic brain injury. , 1996, JAMA.

[10]  T. Mcintosh Novel pharmacologic therapies in the treatment of experimental traumatic brain injury: a review. , 1993, Journal of neurotrauma.

[11]  B. Siesjö,et al.  Mechanisms of secondary brain damage in global and focal ischemia: a speculative synthesis. , 1995, Journal of neurotrauma.

[12]  M. Weller,et al.  Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. , 1994, Journal of neural transmission. Supplementum.

[13]  A. Yakovlev,et al.  Molecular Strategies in CNS Injury , 1995 .

[14]  J. Schulz,et al.  Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: Implications for neurodegenerative diseases , 1996, Neuroscience.

[15]  R. Brubaker Delayed functional loss in glaucoma. LII Edward Jackson Memorial Lecture. , 1996, American journal of ophthalmology.

[16]  R. Bullock,et al.  The role of excitatory amino acids in severe brain trauma: opportunities for therapy: a review. , 1995, Journal of neurotrauma.

[17]  B. Trembly Clinical Potential for the Use of Neuroprotective Agents. A Brief Overview , 1995, Annals of the New York Academy of Sciences.

[18]  M. Schwartz,et al.  Graded crush of the rat optic nerve as a brain injury model: combining electrophysiological and behavioral outcome. , 1990, Restorative neurology and neuroscience.

[19]  S. Thanos,et al.  Treatment of the adult retina with microglia-suppressing factors retards axotomy-induced neuronal degradation and enhances axonal regeneration in vivo and in vitro , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  G. Dunkelberger,et al.  Chronic glaucoma selectively damages large optic nerve fibers. , 1987, Investigative ophthalmology & visual science.

[21]  D. McAdoo,et al.  An experimental model combining microdialysis with electrophysiology, histology, and neurochemistry for exploring mechanisms of secondary damage in spinal cord injury: effects of potassium. , 1993, Journal of neurotrauma.

[22]  A. Faden Pharmacological treatment of central nervous system trauma. , 1996, Pharmacology & toxicology.

[23]  S. Constantini,et al.  An experimental model of closed head injury in mice: pathophysiology, histopathology, and cognitive deficits. , 1996, Journal of neurotrauma.

[24]  D. McAdoo,et al.  Hydroxyl Radicals Generated In Vivo Kill Neurons in the Rat Spinal Cord: Electrophysiological, Histological, and Neurochemical Results , 1994, Journal of neurochemistry.

[25]  T R Holford,et al.  MASCIS evaluation of open field locomotor scores: effects of experience and teamwork on reliability. Multicenter Animal Spinal Cord Injury Study. , 1996, Journal of neurotrauma.

[26]  M. Schwartz,et al.  Optic nerve disease and injury: Prospects for induction of regeneration , 1996, Progress in Retinal and Eye Research.

[27]  J. Grotta Why do all drugs work in animals but none in stroke patients? 2 Neuroprotective therapy , 1995, Journal of internal medicine.

[28]  Michael Belkin,et al.  Temporal parameters of low energy laser irradiation for optimal delay of post-traumatic degeneration of rat optic nerve , 1989, Brain Research.

[29]  E. Yoles,et al.  GM1 reduces injury-induced metabolic deficits and degeneration in the rat optic nerve. , 1992, Investigative ophthalmology & visual science.

[30]  N. Bazan,et al.  Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. , 1995, Journal of neurotrauma.